Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/
Daniel Cohen, CEO Alpega
Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd. Daniel is recognized for pairing strategic focus with disciplined execution, and for building leadership teams and operating cultures capable of sustained high performance. He joins Alpega Group at a pivotal moment, with the mandate and experience to drive its next phase of profitable growth.
“Alpega brings together strong software assets and a meaningful presence across the transportation ecosystem,” said Daniel Cohen. “As the industry becomes more complex and fragmented, the opportunity is to simplify how transportation is managed and executed through solutions that increase trust and efficiency across the value chain. I’m looking forward to working closely with the team and the Board to build on our strong foundation and continue delivering market-leading products, supported by operational excellence and a culture that drives sustained performance.”
Under DeLaughter’s leadership, Alpega Group has strengthened its position as an industry innovator, expanded its product capabilities, and deepened relationships with shippers, carriers, and logistics partners around the world. His guidance has been instrumental in enhancing Alpega’s suite of software solutions and driving sustainable growth across key markets.
Alpega’s platform has evolved from a number of acquisitions including iNet, Transwide, Teleroute, TenderEasy and Wtransnet. This powerful set of tools includes a comprehensive TMS, transport execution capability, freight procurement and freight exchanges which make up Alpega’s digital transportation platform.
The Board expressed deep appreciation for DeLaughter’s leadership and continuity during the transition.
“On behalf of the entire Board, we thank Todd for his exceptional contributions as CEO,” said Chairman Nikolay Pargov. “We are delighted that he will continue to support the company as a trusted advisor. We have a strong conviction that under Daniel's guidance, Alpega will enter a new phase of accelerated growth and innovation. The group has strong foundations, refreshed strategy, and a renewed, very talented leadership team. We continue pursuing our goal to deliver industry-leading performance.”
“It has been a privilege to lead Alpega Group through such an important chapter,” said Todd DeLaughter. “I am incredibly proud of what our teams have accomplished and confident that the company is well-positioned for growth above market expectations, Daniel is a strong, visionary leader, and I look forward to supporting him and the company in my advisory role.”
About Alpega Group
Alpega Group is a leading pan-European logistics software company offering end-to-end solutions that empower shippers, carriers, and logistics professionals to streamline and optimize supply chain operations. With decades of industry expertise, Alpega provides powerful Transportation Management Systems (TMS), a well-connected and collaborative Transport Execution Platform, Freight Exchange solutions, and digital tools that drive efficiency, visibility, and collaboration across the transportation ecosystem.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108528648/en/
Contacts
Media Contact:
Ceren Fuchs
Director of Communications
ceren.fuchs@alpegagroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press Release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press Release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press Release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press Release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press Release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom